MXPA06000991A - Tratamiento de supresion de la dependencia. - Google Patents
Tratamiento de supresion de la dependencia.Info
- Publication number
- MXPA06000991A MXPA06000991A MXPA06000991A MXPA06000991A MXPA06000991A MX PA06000991 A MXPA06000991 A MX PA06000991A MX PA06000991 A MXPA06000991 A MX PA06000991A MX PA06000991 A MXPA06000991 A MX PA06000991A MX PA06000991 A MXPA06000991 A MX PA06000991A
- Authority
- MX
- Mexico
- Prior art keywords
- buprenorphine
- dosage form
- dosage
- days
- withdrawal
- Prior art date
Links
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 abstract 7
- 229960001736 buprenorphine Drugs 0.000 abstract 7
- 239000002552 dosage form Substances 0.000 abstract 4
- 239000006211 transdermal dosage form Substances 0.000 abstract 3
- 208000011580 syndromic disease Diseases 0.000 abstract 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
- B09B—DISPOSAL OF SOLID WASTE NOT OTHERWISE PROVIDED FOR
- B09B2101/00—Type of solid waste
- B09B2101/65—Medical waste
- B09B2101/68—Transdermal patches
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Dermatology (AREA)
- Materials Engineering (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Medical Informatics (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Reverberation, Karaoke And Other Acoustics (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
- Drying Of Semiconductors (AREA)
- Cephalosporin Compounds (AREA)
- Superconductors And Manufacturing Methods Therefor (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49040703P | 2003-07-25 | 2003-07-25 | |
| PCT/US2004/024010 WO2005011579A2 (en) | 2003-07-25 | 2004-07-26 | Treatment of dependence withdrawal |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA06000991A true MXPA06000991A (es) | 2006-04-11 |
Family
ID=34115390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA06000991A MXPA06000991A (es) | 2003-07-25 | 2004-07-26 | Tratamiento de supresion de la dependencia. |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US8637073B2 (enExample) |
| EP (1) | EP1646328B1 (enExample) |
| JP (2) | JP2007500134A (enExample) |
| KR (1) | KR100829492B1 (enExample) |
| CN (1) | CN1829482B (enExample) |
| AT (1) | ATE375149T1 (enExample) |
| AU (1) | AU2004261182B2 (enExample) |
| BR (1) | BRPI0412931A (enExample) |
| CA (1) | CA2530005C (enExample) |
| CY (1) | CY1107262T1 (enExample) |
| DE (1) | DE602004009449T2 (enExample) |
| DK (1) | DK1646328T3 (enExample) |
| EA (1) | EA009921B1 (enExample) |
| ES (1) | ES2295929T3 (enExample) |
| GE (1) | GEP20125454B (enExample) |
| HR (1) | HRP20070476T3 (enExample) |
| IL (1) | IL173346A (enExample) |
| IS (1) | IS2630B (enExample) |
| MA (1) | MA28004A1 (enExample) |
| MX (1) | MXPA06000991A (enExample) |
| NO (1) | NO333189B1 (enExample) |
| NZ (1) | NZ545505A (enExample) |
| PL (1) | PL1646328T3 (enExample) |
| PT (1) | PT1646328E (enExample) |
| SI (1) | SI1646328T1 (enExample) |
| UA (1) | UA81056C2 (enExample) |
| WO (1) | WO2005011579A2 (enExample) |
| ZA (1) | ZA200510069B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
| US7270830B2 (en) * | 2002-12-13 | 2007-09-18 | Purdue Pharma L.P. | Transdermal buprenorphine dosage regimen for analgesia |
| EP1913938A1 (en) * | 2002-12-13 | 2008-04-23 | Euro-Celtique S.A. | Transdermal buprenorphine dosage regimen for analgesia |
| DE602004009449T2 (de) | 2003-07-25 | 2008-07-24 | Euro-Celtique S.A. | Behandlung von entzug |
| KR20080058433A (ko) * | 2005-09-30 | 2008-06-25 | 티티아이 엘뷰 가부시키가이샤 | 오피오이드 작용제 및/또는 오피오이드 길항제를 이용한경피 약물 전달 시스템, 장치 및 방법 |
| US9700552B2 (en) * | 2008-02-28 | 2017-07-11 | Syntropharma Limited | Pharmaceutical compositions for treatment of addiction |
| US8163731B2 (en) * | 2008-08-20 | 2012-04-24 | Rhodes Technologies | Method and dosage regimens for eliminating a chemical substance in blood |
| US9879204B2 (en) | 2010-03-17 | 2018-01-30 | Method Products, Pbc | Liquid cleaning compositions with lower freezing point |
| US11236351B2 (en) | 2010-05-17 | 2022-02-01 | Dow Agrosciences Llc | Production of DHA and other LC PUFAs in plants |
| TW201307553A (zh) | 2011-07-26 | 2013-02-16 | 陶氏農業科學公司 | 在植物中生產二十二碳六烯酸（ｄｈａ）及其他長鏈多元不飽和脂肪酸（ｌｃ－ｐｕｆａ）之技術 |
| ES2716570T3 (es) | 2012-04-17 | 2019-06-13 | Purdue Pharma Lp | Sistemas y procedimientos para tratar o prevenir una respuesta farmacodinámica adversa inducida por opioides |
| US9849124B2 (en) | 2014-10-17 | 2017-12-26 | Purdue Pharma L.P. | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
| EP3400066B1 (en) * | 2016-01-08 | 2021-07-28 | Ohio State Innovation Foundation | Treatments and prevention of opioid neonatal abstinence syndrome |
| JP2020526500A (ja) | 2017-06-30 | 2020-08-31 | パーデュー、ファーマ、リミテッド、パートナーシップ | 治療方法及びその剤形 |
| CN107648234A (zh) * | 2017-08-04 | 2018-02-02 | 中国人民解放军第二军医大学 | 一种治疗吗啡成瘾戒断症状的阿片类药物组合物 |
| CA3066284A1 (en) * | 2018-04-09 | 2019-10-17 | Katana Pharmaceuticals, Inc. | Oxytocin compositions and methods of use |
| AU2020342591A1 (en) | 2019-09-02 | 2022-03-03 | Camurus Ab | Formulations and treatment methods |
| EP4284506A4 (en) | 2021-02-01 | 2024-12-25 | Clear Scientific, Inc. | SEQUESTRATION COMPOUNDS FOR THE TREATMENT OF SUBSTANCE USE DISORDER AND USES THEREOF |
| EP4568672A2 (en) * | 2022-08-12 | 2025-06-18 | Bioventures, Llc | Deuterated buprenorphine as a protective agent for fetal subjects against full-agonist opioid exposure |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4058599A (en) | 1973-02-24 | 1977-11-15 | Bayer Aktiengesellschaft | Ethyleneimine inactivated organisms |
| DE3939376C1 (enExample) | 1989-11-29 | 1991-05-08 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De | |
| US5075341A (en) * | 1989-12-01 | 1991-12-24 | The Mclean Hospital Corporation | Treatment for cocaine abuse |
| EP0432945A1 (en) * | 1989-12-12 | 1991-06-19 | Warner-Lambert Company | A transdermal delivery system for treatment of cocaine and heroin addiction |
| US5272149A (en) * | 1992-05-05 | 1993-12-21 | Stalling Reginald W | Symptom controlled receptor substitution for addiction withdrawl |
| JPH06183956A (ja) * | 1992-12-24 | 1994-07-05 | Teisan Seiyaku Kk | 安定な貼付用の製剤 |
| JP2819236B2 (ja) * | 1994-05-06 | 1998-10-30 | 日東電工株式会社 | 経皮吸収製剤 |
| EP0821957A3 (en) | 1996-08-01 | 1998-04-22 | Eli Lilly And Company | Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating substance abuse |
| US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
| KR100383252B1 (ko) | 1998-12-17 | 2003-07-16 | 주식회사 삼양사 | 부프레놀핀을함유하는경피투여조성물및이를포함하는패취 |
| AU2002348135A1 (en) * | 2001-10-31 | 2003-05-12 | Recovery Pharmaceuticals, Inc. | Methods for the treatment of addiction |
| PT1485051E (pt) | 2002-03-20 | 2008-07-09 | Euro Celtique Sa | Processo de administração da buprenorfina para o tratamento da depressão |
| US7270830B2 (en) | 2002-12-13 | 2007-09-18 | Purdue Pharma L.P. | Transdermal buprenorphine dosage regimen for analgesia |
| WO2004103317A2 (en) | 2003-05-15 | 2004-12-02 | Euro-Celtique S.A. | Transdermal buprenorphine dosage regimen for treatment of diarrhea |
| DE602004009449T2 (de) | 2003-07-25 | 2008-07-24 | Euro-Celtique S.A. | Behandlung von entzug |
-
2004
- 2004-07-26 DE DE602004009449T patent/DE602004009449T2/de not_active Expired - Lifetime
- 2004-07-26 US US10/566,121 patent/US8637073B2/en active Active
- 2004-07-26 JP JP2006521307A patent/JP2007500134A/ja active Pending
- 2004-07-26 PL PL04779186T patent/PL1646328T3/pl unknown
- 2004-07-26 MX MXPA06000991A patent/MXPA06000991A/es active IP Right Grant
- 2004-07-26 SI SI200430545T patent/SI1646328T1/sl unknown
- 2004-07-26 AT AT04779186T patent/ATE375149T1/de active
- 2004-07-26 KR KR1020067001688A patent/KR100829492B1/ko not_active Expired - Fee Related
- 2004-07-26 EP EP04779186A patent/EP1646328B1/en not_active Expired - Lifetime
- 2004-07-26 GE GEAP20049184A patent/GEP20125454B/en unknown
- 2004-07-26 WO PCT/US2004/024010 patent/WO2005011579A2/en not_active Ceased
- 2004-07-26 ES ES04779186T patent/ES2295929T3/es not_active Expired - Lifetime
- 2004-07-26 NZ NZ545505A patent/NZ545505A/en not_active IP Right Cessation
- 2004-07-26 PT PT04779186T patent/PT1646328E/pt unknown
- 2004-07-26 AU AU2004261182A patent/AU2004261182B2/en not_active Ceased
- 2004-07-26 CA CA2530005A patent/CA2530005C/en not_active Expired - Fee Related
- 2004-07-26 DK DK04779186T patent/DK1646328T3/da active
- 2004-07-26 BR BRPI0412931-8A patent/BRPI0412931A/pt not_active Application Discontinuation
- 2004-07-26 CN CN2004800215633A patent/CN1829482B/zh not_active Expired - Fee Related
- 2004-07-26 UA UAA200602136A patent/UA81056C2/uk unknown
- 2004-07-26 EA EA200600200A patent/EA009921B1/ru not_active IP Right Cessation
- 2004-07-26 HR HR20070476T patent/HRP20070476T3/xx unknown
-
2005
- 2005-12-12 ZA ZA200510069A patent/ZA200510069B/en unknown
- 2005-12-19 IS IS8187A patent/IS2630B/is unknown
-
2006
- 2006-01-24 IL IL173346A patent/IL173346A/en not_active IP Right Cessation
- 2006-02-23 MA MA28830A patent/MA28004A1/fr unknown
- 2006-02-24 NO NO20060913A patent/NO333189B1/no not_active IP Right Cessation
-
2008
- 2008-01-08 CY CY20081100020T patent/CY1107262T1/el unknown
-
2011
- 2011-08-18 JP JP2011179129A patent/JP2011252020A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1107262T1 (el) | Θεραπεια της εξαρτησης στερησης | |
| AU2003268144A1 (en) | Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist | |
| CA2302754A1 (en) | Noribogaine in the treatment of pain and drug addiction | |
| AU4743601A (en) | Neutral antagonists and use thereof in treating drug abuse | |
| CY1108217T1 (el) | Μεθοδος χορηγησης βουπρενορφινης για τη θεραπεια της καταθλιψης | |
| SI1476141T1 (sl) | Naprave za transdermalno dajanje opoida, zaščitene pred nedovoljenimi posegi | |
| NZ540385A (en) | Use of 1-oxo-2-(2, 6-dioxopiperidin-3-yl)-4-methylisoindoline in the manufacture of a medicamnent for treatment of brain cancer | |
| JP2002523370A5 (enExample) | ||
| SI1572167T1 (sl) | Transdermalni buprenorfinski dozirni reĹľim za analgezijo | |
| WO1992002234A3 (en) | Reduction or prevention of sensitization to drugs | |
| JP2004537500A5 (enExample) | ||
| ATE405272T1 (de) | Behandlung von t-zellen-lymphom mittels 10- propargyl-10-deazaaminopterin | |
| ATE310509T1 (de) | Methode zur behandlung eines analgesiebedürftigen patienten | |
| UA81689C2 (ru) | Способ предоперационного лечения послеоперационной боли бупренорфином | |
| Naber et al. | Repeated high dosage naloxone treatment without therapeutic efficacy in schizophrenic patients | |
| DE60121449D1 (de) | Behandlung von hepatitis c mit thymosin und pegyliertem interferon |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |